Psychotropic medication during endocrine treatment for breast cancer
Open Access
- 6 August 2011
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 20 (7) , 1533-1540
Abstract
Purpose Psychological problems are frequently mentioned in women treated for breast cancer in whom depression is mentioned as the most common disorder. The aim was to study the prescription of psychotropic medication in women with endocrine treatment for breast cancer in women in our prospective and consecutive pharmacy database. Methods Women (n = 2,172) with at least one prescription of tamoxifen, fulvestrant, anastrazole, letrozole or exemestane were considered as breast cancer patients treated with endocrine therapy. This group was compared with an age- and family physician-matched group of women without cancer (n = 8,129), and the incidence risk ratio (IRR) and the 95% confidence intervals (95% CI) were calculated. In addition, the prevalence of these psychotropic medication prescriptions and the 95% CI were calculated. Results There was an increased prescription of psychotropic medication in the female breast cancer patients on endocrine therapy: anxiolytics (IRR 2.07, 95% CI 1.87–2.29), hypnotics and sedatives (IRR 2.59, 95% CI 2.34–2.87) and anti-depressants (IRR 1.46, 95% CI 1.28–1.65). The prevalences of anxiolytics, hypnotics and sedatives were also increased in this group, indicating an increased use over time of these drugs. The prevalence of anti-depressant prescription was not increased, indicating short-term use only. Conclusions This study indicated increased psychological distress due to breast cancer diagnosis and/or treatment in women on endocrine therapy. Anti-depressants were only prescribed for a short time. These data can contribute to an improved awareness of the impact of breast cancer (treatment) and therefore potentially to the optimizing of support for these patients.Keywords
This publication has 22 references indexed in Scilit:
- Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashesMenopause, 2010
- Ameliorating hot flashes/awakenings in the context of breast cancer treatmentsMenopause, 2010
- Coprescription of Tamoxifen and Medications That Inhibit CYP2D6Journal of Clinical Oncology, 2010
- LHRH agonists for adjuvant therapy of early breast cancer in premenopausal womenCochrane Database of Systematic Reviews, 2009
- Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenCochrane Database of Systematic Reviews, 2009
- Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007Journal of Experimental & Clinical Cancer Research, 2008
- Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over studyBreast Cancer Research and Treatment, 2008
- Depression, quality of life and breast cancer: a review of the literatureBreast Cancer Research and Treatment, 2007
- Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast CancerClinical Cancer Research, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005